Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 1, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2026

Conditions

Endometrial CancerEndometrial Adenocarcinoma

Interventions

DRUG

Cadonilimab

Injectable solution

DRUG

Carboplatin

Injectable solution

DRUG

Cisplatin

Injectable solution

DRUG

Paclitaxel

Injectable solutionS

All Listed Sponsors

collaborator

Fujian Provincial Hospital

OTHER

collaborator

The First Affiliated Hospital of Nanchang University

OTHER

collaborator

Zhangzhou Affiliated Hospital of Fujian Medical University

OTHER

collaborator

The First Affiliated Hospital of Bengbu Medical University

OTHER

lead

Fujian Cancer Hospital

OTHER_GOV

NCT06066216 - Cadonilimab (AK104) Plus Chemotherapy in Patients With Recurrent or Advanced Endometrial Cancer | Biotech Hunter | Biotech Hunter